News

November 29th

Compound dissolves HIV on contact

The ability of the synthetic compound known as “PD 404,182″ to break apart the AIDS-causing virus before it can infect cells was discovered by Zhilei Chen, assistant professor of chemical engineering at Texas A&M University, and her team of researchers. Their findings appear in the journal Antimicrobial Agents and Chemotherapy.


November 28th

Resverlogix Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled. The Cleveland Clinic leads this trial in which all subjects have established atherosclerotic cardiovascular disease (CVD) and low high-density cholesterol (HDL-C). In SUSTAIN, all subjects will receive standard of care therapy that includes up to 40 mg atorvastatin (Lipitor) or 20 mg rosuvastatin (Crestor). Despite the standard of care therapy in the SUSTAIN population, the risk of recurrent CVD events remains exceedingly high. Thus this patient population presents an ideal opportunity to test the effects of placebo vs. RVX-208 (200 mg/day) an orally active small molecule that raises ApoA-I production and thereby increases HDL-C.


November 28th

Dr. Paul Marks Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin(TM)

BEVERLY, MA, Nov 28, 2011 (MARKETWIRE via COMTEX) — Cellceutix Corporation CTIX 0.00% (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that Dr. Paul Marks has joined the Cellceutix Scientific Advisory Board.


November 28th

World Diabetes Congress Builds on Momentum From UN Summit

November 28, 2011 (Dubai, United Arab Emirates) — In what it is calling “a landmark year” after the United Nations High-Level Meeting on Prevention and Control of Non-communicable Diseases (UN NCD Summit) held in New York on September 19-20, the International Diabetes Federation (IDF) plans to “continue the momentum” with the World Diabetes Congress starting in Dubai December 4, 2011.


November 28th

Damage From Alzheimer’s Disease Reversed With Deep Brain Stimulation

Applying electrical pulses directly into targeted areas of the brain appears to reverse some of the damage caused by Alzheimer’s disease and may even improve cognitive function and memory, according to Dr Andres M. Lozano and his team at Toronto Western Hospital in Ontario, Canada, who carried out a small study into the effects of deep brain stimulation on patients with early signs of the disease.


November 23rd

Peregrine reports over 23 month overall survival from phase 2 breast cancer study

Peregrine Pharmaceuticals (NASDAQ:PPHM) saw its shares rise over 13 percent on Tuesday after it reported a median overall survival of more than 23 months from its phase two breast cancer drug study. The phase 2 single-arm trial evaluated bavituximab in combination with two chemotherapy drugs, carboplatin and paclitaxel, in patients with locally advanced, or metastatic (spread), breast cancer.


November 23rd

Gilead’s $11 Billion Gambit: Hefty Premium Paid for Tiny Pharmasset Reflects Potential of Hepatitis C Market

Gilead Sciences Inc.’s agreement to pay nearly $11 billion to acquire tiny Pharmasset Inc. is a dramatic illustration of the market potential—and public-health challenges—involved in the battle against the hepatitis C virus.


November 23rd

Contract Packaging Business Trends: Pharma’s in flux; how are packagers responding?

Branded pharma sales may be in a sluggish growth phase, but contract packagers are still seeing plenty of opportunities as new markets open up, new forms grow in acceptance, and new regulations and drug technologies push package requirements. We spoke to several contract packagers and suppliers to get a feel for the current state of this multi-billion-dollar business.


November 22nd

Data from Phase 2 Study of Dexpramipexole In ALS Published in Nature Medicine

PITTSBURGH, Nov 21, 2011 (BUSINESS WIRE) — Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis (ALS). Dexpramipexole is currently in Phase 3 development under an exclusive worldwide license with Biogen Idec.


November 22nd

NormOxys lands $600K financing

Small-molecule therapeutics firm NormOxys Inc. has taken in a small amount of funding in its $600,000 financing of debt and secured convertible notes, the Wellesley company noted in a regulatory filing.